BIOTECH ASSISTANT / FIELD NOTES

Codis moves commercial-scale ASD spray-drying expansion into construction

Company / institutional announcement · Codis

Source published:

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

What changed

Codis has moved its Haverhill expansion into construction after completing demolition of redundant facilities. The project will add a solvent-capable GEA PSD-4 spray dryer for commercial-scale amorphous solid dispersions and connect with formulation, analytical, clinical supply, and oral solid dose services in Nottingham. Additional capacity is expected in the fourth quarter of 2027, after installation and validation.

Why it may matter

Sponsors developing poorly soluble drugs gain a potential future ASD supply option, although equipment acceptance and validation remain key execution milestones.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Formulation Development & Manufacturing

Related updates

Phillips Medisize / Business Wire

Phillips Medisize acquires full Chippenham site footprint for inhalation development

Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.

PharmAla Biotech / GlobeNewswire

PharmAla engages Corealis for ALA-002 formulation and clinical GMP supply

PharmAla signed an agreement with Corealis Pharma for ALA-002 drug-product development and GMP clinical supply. Corealis has begun formulation work in Laval, Québec, with an initial 50 mg capsule planned. Manufacturing of the first GMP batch is conditional on completing development activities. The agreement establishes a development and supply arrangement, rather than a product approval.

Frontiers in Chemistry

Review examines cocrystal performance and barriers to clinical translation

A Frontiers in Chemistry review examines pharmaceutical cocrystals as a way to modify dissolution and related biopharmaceutical properties without changing an API's chemical identity. The abstract distinguishes solubility-limited BCS II drugs from permeability-limited BCS IV drugs. It highlights gastrointestinal instability, manufacturing reproducibility, coformer selection, and limited pharmacokinetic evidence. Much of the reported performance evidence remains preclinical.

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗
AI assistant ↗